Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

Fig. 1

Progression-free survival by BMI shows heterogeneous trends when stratifying by clinical features. Progression-free survival in (a) the entire MM cohort, b the MM patients who received first-line ICI, c the MM patients who received non-first-line ICI, d the MM patients who received anti-CTLA4 treatment, e the MM who received anti-PD1 treatment, and (f) the MM patients who received combination treatment. All p-values are from the log-rank tests

Back to article page